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The Calcium-Sensing Receptor (CaSR) is a G-protein coupled, 7-transmembrane
domain receptor ubiquitously expressed throughout the body, brain including. The role of
CaSR in the CNS is not well understood; its expression is increasing during development,
which has been implicated inmemory formation and consolidation, and CaSR localization
in nerve terminals has been related to synaptic plasticity and neurotransmission.
There is an emerging evidence of CaSR involvement in neurodegenerative disorders
and Alzheimer’s disease (AD) in particular, where the over-production of β-amyloid
peptides was reported to activate CaSR. In the present study, we performed CaSR
immunohistochemical and densitometry analysis in the triple transgenic mouse model
of AD (3xTg-AD). We found an increase in the expression of CaSR in hippocampal CA1
area and in dentate gyrus in the 3xTg-ADmice when compared to non-transgenic control
animals. This increase was significant at 9 months of age and further increased at 12
and 18 months of age. This increase paralleled the accumulation of β-amyloid plaques
with age. Increased expression of CaSR favors β-amyloidogenic pathway following direct
interactions between β-amyloid and CaSR and hence may contribute to the pathological
evolution of the AD. In the framework of this paradigm CaSR may represent a novel
therapeutic target.
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INTRODUCTION
The calcium sensing receptor (CaSR) belongs to the extended family of plasmalemmal G protein-
coupled heptahelical receptors (GPCRs); it shares the C subfamily of GPCRs with metabotropic
glutamate receptors (mGluR) and γ-aminobutyric acid GABAB receptors (Brown and MacLeod,
2001). CaSRs are widely distributed throughout the brain, with highest expression in the
Abbreviations: AD, Alzheimer’s disease; ANOVA, One-way Analysis of Variance; CaSR, Calcium-Sensing Receptor; DG,
Dentate Gyrus; GCL, Granular Cell Layer; IOD, Inverted Optical Density; mGluR, metabotrobic Glutamate Receptors;
ML, Molecular Layer; OD, Optical Density; PB, Phosphate Buffer; PCL, Pyramidal Cell Layer; S.Mol, Stratum Lacunosum-
Moleculare; SO, Stratum Oriens; S.Rad, Stratum Radiatum; TS, Trizma-base Saline; VEGF, Vascular Endothelial Growth
Factor; 3xTg-AD, triple Transgenic mouse model of AD.
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subfornical organ, hippocampus, striatum, cingulate cortex,
cerebellum, ependymal zones of the cerebral ventricles and
perivascular nerves around cerebral arteries, some CaSR
expressing cells were found also in rat dorsal root ganglia (Ruat
et al., 1995; Yano et al., 2004). The CaSR has been found
abundantly expressed in vivo in neurons and in oligodendrocytes;
in vitro studies demonstrated its expression in human primary
astrocytes and in rat microglia (Ruat et al., 1995; Chattopadhyay
et al., 1998, 1999a; Ferry et al., 2000; Dal Prà et al., 2005).
Numerous functions have been assigned to CaSR in the
CNS from regulation of neuronal growth and migration, to
the role in neurotransmission and synaptic plasticity (Ruat and
Traiffort, 2013); CaSR can also contribute to astroglial functions,
microglial reactivity and oligodendroglial development (Ruat
and Traiffort, 2013). The level of extracellular ionized Ca2+
([Ca2+]o) is usually considered to be stable in the brain, which
is not really the case, since [Ca2+]o undergoes rapid fluctuations
in normal physiological processes such as development, synaptic
transmission and aging as well as in pathological processes
including neurodegeneration and Alzheimer’s disease (AD;
Small, 2009; Ruat and Traiffort, 2013).
Expression of CaSR markedly increases during development,
specifically in perinatal and early post-natal periods just before
and after birth (Chattopadhyay et al., 1997; Vizard et al., 2008).
In the hippocampus CaSR was reported to regulate neuronal
growth, as well as extension and branching of neurites (Vizard
et al., 2008). In addition, CaSR has been identified in neocortical
nerve terminals where it senses the [Ca2+]o and activates voltage
dependent non-selective cation channels (NSCCs) (Chen et al.,
2010). It has been proposed that the decrease in [Ca2+]o in
the synaptic cleft may act as feedback to presynaptic CaSR and
the associated increased activity of NSCCs may prolong action
potentias; in this way CaSR may influence synaptic transmission
through a homeostatic pathway to prevent synaptic failure when
[Ca2+]o falls (Ye et al., 1996). Studies in vitro conducted in the
human astrocytoma cell line U87, and in primary cultures of
rat microglia and oligodendroglia showed that CaSR stimulates
Ca2+-activated K+ channels, thus contributing to local ionic
homeostasis following the lowering of [Ca2+]o due to increased
neuronal activity; there are also indications that CaSR could also
play a role in microglia activation (Chattopadhyay et al., 1998,
1999a,b). CaSR can form heterodimers with others GPCRs, like
GABAB receptors and mGluRs, which might be important for
their trafficking to the membrane, their ligand binding sensitivity
and thus the regulation of signaling responses (Gama et al., 2001;
Chang et al., 2007). Activation of CaSR was also demonstrated to
induce a distinct form of glutamate release independent on Ca2+
influx (Vyleta and Smith, 2011).
In the context of AD, CaSR has been reported to be directly
activated by β-amyloid as well as by apoE (isoforms 3 and 4)
(Conley et al., 2009). In rat hippocampal neurons exposure to β-
amyloid stimulated openings of NSCCs linked to CaSR activation
(Ye et al., 1997). How β-amyloid interacts with CaSR remains
unclear, although it is possible that either β-amyloid fibrils or
variously sized oligomers, having regular positive charges, mimic
CaSR agonists, or hydrophobic interactions between β-amyloid
and CaSR may take place (Ye et al., 1997). Thus, extracellular
accumulation of β-amyloid can activate CaSRwhich, in turn, may
contribute to Ca2+ dyshomeostasis observed in AD (Lim et al.,
2014, 2015).
Previous studies on human cultured primary adult astrocytes
showed that their exposure to exogenous β-amyloid25–35, a
surrogate of β-amyloid42, triggers CaSR-dependent signaling
cascade that stimulates the expression of nitric oxide synthase-
2 (NOS-2) followed by an excessive release of nitric oxide
(Chiarini et al., 2005), and increased expression of vascular
endothelial growth factor (VEGF)-A (Chiarini et al., 2010). Most
importantly, cultured human cortical astrocytes and neurons
exposed to β-amyloid25–35, which binds and activates CaSR (Dal
Prà et al., 2014), begin to excessively produce and secrete β-
amyloid42 oligomers, contributing in this way to the β-amyloid
load (Dal Prà et al., 2011; Armato et al., 2013).
In the present study, for the first time we aimed to determine
in vivo CaSR expression in the 3xTg-AD mouse model and
correlate its changes with β-amyloid load.
MATERIALS AND METHODS
All animal procedures were carried out in accordance with the
United Kingdom Animals (Scientific Procedures) Act of 1986
under the license from the Home Office. All efforts were made to
reduce the number of animals by following the 3R’s (reduction,
refinement and replacement).
Mice
Experiments were performed on male 3xTg-AD mice generated
on 129/C57BL6 background (the wild type of which was
employed as a non-Tg control). The 3xTG-AD mice harbor
the mutant genes for amyloid precursor protein (APPSwe),
presenilin 1 PS1M146V and tauP301L (Oddo et al., 2003a,b;
Rodríguez et al., 2008). All 3xTg-AD and non-Tg control mice
were obtained by crossing homozygous breeders. Animals were
housed in groups of the same genotype and in the same cage
according to their age, kept in 12 h light-dark cycles with ad
libitum access to food and water.
The experimental groups chosen were of 9, 12, and 18 months
of age, since it is at these ages that the amyloid and tau
pathologies emerge resembling the human Alzheimer’s disease
progression. Indeed, the 3xTg-AD mice exhibit the highest
intracellular β-amyloid deposition at 9 months of age, they start
showing extracellular β-amyloid plaques followed by intracellular
tau deposition at 12 months of age and they present massive
Aβ plaques and neurofibrillary tangles at 18 months of age
(Rodríguez et al., 2008; Olabarria et al., 2010).
Fixation and Tissue Processing
As described previously (Olabarria et al., 2010; Kulijewicz-
Nawrot et al., 2012) 3xTg-AD and non-Tg control mice at 9,
12, 18 months of age (Ns for non-Tg = 5, 5, 4; ns for 3xTg-
AD = 4, 5, 3, respectively) were intraperitoneally anesthetized
with sodium pentobarbital (50 mg/kg). Mice were trans-cardially
perfused with 4% paraformaldehyde (PFA, Sigma, UK) and
0.1 M phosphate buffer (PB) at pH 7.4. Brains were removed
and post-fixed in 4% paraformaldehyde overnight, then cut
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FIGURE 1 | CaSR expression and localization in hippocampus. Brightfield micrographs showing the distribution of CaSR-IR within the dorsal hippocampus of
18 months old non-Tg controls (A,C,E,G,I) and 3xTg-AD mice (B,D,F,H,J; arrowheads show neuropil elements, whilst full arrows indicate interneurons). Confocal
micrographs showing the immunoreactivity for CaSR (red) and for GFAP (green), in Non-Tg (K–M) and 3xTg-AD mice (N–P). Inserts in (N–P) show an astrocyte
bearing CaSR at higher magnification (scale bar 20 µm). CA1, Cornu Ammonis 1; DG, Dentate Gyrus; St Rad, Stratum Radiatum; St Lac, Stratum
Lacunosum-Moleculare; Mol L, Molecular Layer; GCL, Granular Cell Layer.
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into 4–5 mm coronal slabs of tissue containing the entire
rostrocaudal extent of the hippocampus, as previously described
(Olabarria et al., 2011). The tissue was further sectioned in 40–
50 µm-thick slices with a vibrating microtome (VT1000S, Leica,
Milton Keynes, UK). Free floating sections were collected in
0.1 M PB and stored in a cryoprotectant solution containing
25% sucrose and 3.5% glycerol in 0.05 M PB at pH 7.4.
Three coronal sections at levels −1.58 mm/−2.46 mm (dorsal
hippocampus) posterior to Bregma, were selected from each
animal for immunohistochemistry according to the mouse brain
atlas of Paxinos and Franklin (2012).
Antibodies
A mouse monoclonal anti-Calcium Sensing Receptor antibody
(anti-CaSR; Sigma-Aldrich, UK; C0493) was used for the
determination of CaSR expression throughout the dorsal
hippocampus. For the identification of intracellular β-amyloid
deposits and plaques a monoclonal mouse antibody that reacts
with abnormally processed isoforms, as well as precursor forms
of Aβ, recognizing an epitope within amino acids 3–8 (EFRHDS;
anti-Aβ 6E10 [SIG-39320] Signet Laboratories, Dedham, MA)
was used, for hyperphosphorylated Tau we employed the mouse
monoclonal antibody anti-PHF Tau AT8 (Innogenetics, Gent,
Belgium). For double immunostaining of CaSR with GFAP and
Aβ, a rabbit anti-GFAP (Sigma-Aldrich, UK; G9269) and a
mouse anti-Aβ Alexa 488 6E10 conjugated antibody (Covance,
USA) were used. To assess for non-specific background labeling
or cross reactivity between antibodies derived from different
host species, a series of control experiments were performed,
including the omission of primary (Supplementary Figure 1C)
and/or secondary antibodies from the incubation solutions;
resulting all of them in a total absence of target labeling.
Immunohistochemistry
All the sections were processed at the same time using the same
experimental conditions to minimize methodological variability
(Noristani et al., 2010; Olabarria et al., 2011; Kulijewicz-Nawrot
et al., 2012). Then sections were incubated for 30 min in 30%
methanol in 0.1 M PB and 30% hydrogen peroxide (H2O2;
Sigma, UK). Sections were then rinsed with 0.1 M PB for 5
min and placed in 1% sodium borohydride (Sigma, UK) for
30 min. The sections were then washed with PB profusely
before rinsing in 0.1 M Trizma base saline (TS) for 10 min.
Brain sections were then incubated in 0.5% bovine serum
albumin (Sigma, UK) in 0.1 M TS and 0.25% Triton X-100
(Sigma, UK) for 30 min. Sections were incubated for 72 h
at room temperature in primary antibody (mouse anti-CaSR,
1:250, Sigma, UK). The sections were rinsed in 0.1 M TS for
30 min and incubated in 1:400 dilutions of biotinylated horse
anti-mouse IgG (Vector Laboratories, Peterborough, UK) for 1
h at room temperature. Sections were rinsed with 0.1 M TS
for 30 min followed by incubation for 30 min in avidin-biotin
peroxidase complex (Vector Laboratories, Peterborough, UK).
The peroxidase reaction product was visualized by incubation
in a solution containing 0.022% of 3,3’ diaminobenzidine (DAB,
Aldrich, Gilligham, UK) and 0.003% H2O2 for 7 min. The
reaction was stopped by rinsing the sections in 0.1 M TS
FIGURE 2 | Changes of CaSR expression in hippocampal CA1. Bar
graphs illustrating CaSR-IR IOD within CA1 subfield of hippocampus between
non-Tg controls and 3xTg-AD mice at 9, 12 and 18 months of age (Ns for
non-Tg = 5, 5, 4; ns for 3xTg-AD = 4, 5, 3, respectively; 3 slices have been
analyzed per each animal). (A) Total CA1, (B) CA1 Pyramidal Cell Layer,
(C) CA1 Stratum Radiatum, (D) CA1 Stratum Lacunosum-Moleculare. Bars
represent means ± SEM (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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TABLE 1 | Summary of CaSR IOD values in the hippocampal CA1 and DG subfields and their respective layers in both non-Tg and 3xTg-AD.
CaSR IOD 9 months NTG 9 months 3xTG-AD 12 months NTG 12 months 3xTG-AD 18 months NTG 18 months 3xTG-AD
Total CA1 82.71 ± 2.98 102.1 ± 2.72*** 83.92 ± 2.51 98.71 ± 2.56*** 93.51 ± 3.39 112.30 ± 4.68**
PCL CA1 115.20 ± 3.78 127.50 ± 3.80* 114.00 ± 2.49 116.60 ± 2.39ns 108.60 ± 4.57 130.50 ± 3.40**
St Rad CA1 74.23 ± 2.91 83.83 ± 3.60* 75.08 ± 2.85 91.38 ± 2.75*** 91.23 ± 3.31 104.5 ± 5.99*
St Lac CA1 53.78 ± 2.60 103.9 ± 3.33*** 59.53 ± 2.71 83.09 ± 4.41*** 66.25 ± 5.31 103.4 ± 6.25***
Total DG 82.68 ± 3.11 97.41 ± 3.56** 81.35 ± 3.33 93.34 ± 2.80** 89.78 ± 4.75 108.40 ± 4.96*
ML 73.06 ± 3.16 84.68 ± 4.88* 80.58 ± 4.18 90.51 ± 3.01* 90.00 ± 4.11 108.8 ± 6.91*
GCL 98.30 ± 3.55 117.30 ± 4.27** 87.76 ± 3.15 97.13 ± 2.78* 82.18 ± 6.16 112.90 ± 3.54***
Values are expressed as means ± SEM (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
for 5 min followed by 0.1 M PB for 15 min. Brain sections
were permanently mounted onto gelatinized slides and allowed
to dry overnight. Sections were then dehydrated in ascending
concentration of ethanol (50, 70, 80, 90, 95, and 100%)
and, finally, xylene. Sections were then permanently mounted
and coverslipped using Entellan (Merck KGaA, Darmstadt,
Germany) and slides were left to dry overnight.
For the dual immunofluorescence labeling with CaSR and
GFAP the sections were simultaneously incubated with both
antibodies (mouse anti-CaSR, 1:250; rabbit anti-GFAP, 1:20,000)
for 48 h at room temperature. Then CaSR and GFAP were
detected in a sequential manner on the same sections by
incubation of 2 h with Alexa Fluor 594-conjugated goat anti-
mouse and Alexa Fluor 488-conjugated goat anti-rabbit (1:400,
Invitrogen, Paisley, UK), respectively.
For the dual immunofluorescence labeling with CaSR and Aβ
the sections were first incubated for 48 h at room temperature
in CaSR antibody solution then in the Alexa 594 conjugated
goat anti-mouse for 2 h, finally for 24 h in Alexa 488-conjugated
mouse anti-Aβ antibody (1:1,000, Covance, USA).
Sections were rinsed with 0.1 M TS for 30 min and
permanently mounted in an aqueous medium (Vectashield;
Vector laboratories, Peterborough, UK).
Optical Density (OD) Measurement
Using computer-assisted imaging analysis (ImageJ 2.0.0-rc-
39/1.50b; NIH, USA) we analyzed the expression of CaSR by
measuring its OD, as described previously (Cordero et al., 2005;
Noristani et al., 2010, 2012). Briefly, to exclude any experimental
errors and/or bias, all images were taken at constant light
intensity with a Nikon Eclipse 80i microscope coupled with an
8001 MicroFIRE camera. Optical filters were used to ensure
the specificity of the signal recorded by the camera. The OD
was calculated from a relative scale of intensity ranking from
0 to 250, with a measurement of 250 corresponding to the
area with very low CaSR expression and 0 corresponding to
the area with highest labeling. The calibration density was
kept constant for measuring all sections to avoid experimental
variances. Non-specific OD in sections was measured from
the corpus callosum (CC). CaSR density of the complete CA
subfields of the hippocampus and their different layers (stratum
pyramidale, PCL; stratum oriens, SO; stratum radiatum, S.Rad
and stratum lacunosum-moleculare, S.Mol), except CA3 where
we also studied stratum lucidum, were measured independently.
Similarly, CaSR density of the dentate gyrus (DG) and its
different layers (granular cell layer, GCL, molecular layer,
ML and hilus) were measured individually. The OD of the
region of interest is determined by outlining each layer and
obtaining the mean value of the intensities in the selected area
(Supplementary Figures 1A,B). The changes in CaSR density
were analyzed against a constant control region (CC): 250 was
divided by control region and the obtained factor was multiplied
by the region of interest in every given section. Inverse OD (IOD)
was obtained by subtracting the OD (after the control region
normalization) from 250. Values of IODwere taken and averaged
in both the left and right hemisphere of each slice. The results are
shown as inverse optical CaSR density (IOD/pixel).
Counting of Aβ-Positive Cells
β-amyloid containing neurons were counted in the entire extent
of the CA1 region of the hippocampus, since this field shows the
earliest and strongest accumulation of Aβ intracellular deposits.
This quantification was carried out on six non-consecutive
sections from dorsal hippocampus of three non-Tg and 3xTg-AD
animals of 9 months of age immunolabeled with anti-Aβ 6E10
antibody.
Statistical Analysis
One-way analysis of variance (ANOVA) was used to determine
changes in CaSR density between 3xTg-AD animals and their
non-transgenic controls at different ages, followed by unpaired
t-test comparisons at the different time points. Significance was
accepted at P ≤ 0.05. The data were analyzed using GraphPad
Prism software (La Jolla, CA, USA). Results are expressed as
mean± SEM.
RESULTS
Immunohistochemical labeling demonstrated that CaSR is
present in the hippocampus of both 3xTg-AD and non-Tg
control animals at all ages (9, 12, and 18 months) with a rather
homogeneous distribution throughout all hippocampal areas
(Figures 1A,B). Punctate CaSR labeling is mainly present in
pyramidal neurons of the different CA subfields and in granule
cells of the DG as well as in the pleomorphic cells of the hilus,
being more evident in the soma, nucleus excluded, although it
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is also detectable in the neuropil, including both dendrites and
axons (Figures 1C–F). Astroglial occurrence of CaSR was rather
rare and when detected was of very low intensity as compared to
neurons; appearing as puncta mainly restricted to the astrocytic
soma (Figures 1K–P).
Increase of CaSR Expression in 3xTg-AD
Animals
Optical density analysis of CaSR staining in the hippocampus
of the 3xTg-AD mouse showed a significant increase in its
expression in CA1 and DG subfields [F(7, 166) = 11.32, p< 0.0001
and F(7, 166) = 7.994, p < 0.0001, respectively] at all ages (9,
12, and 18 months; Figures 1, 2). An increase in CaSR optical
density of 23.44, 17.62, and 20.09% at 9, 12, and 18 months
of age respectively when compared to control non-Tg animals
was detected in CA1 area (Figures 1C,D, 2A; Table 1). Similar
increase in CaSR optical density was observed in DG: 17.82,
14.74, and 20.74%, at 9, 12, and 18 months respectively in 3xTg-
AD animals compared to non-Tg (Figures 1E,F, 3A; Table 1).
No significant alterations in the optical density of CaSR were
identified in the CA2 and in CA3 sub-fields.
CaSR Expression Increase in CA1 and DG
Is Layer-Specific
In CA1 we found that the increase in CaSR expression in 3xTg-
AD animals mainly occurred in the pyramidal cell layer (PCL,
10.68% at 9 months, 2.28% at 12 months, 20.17% at 18 months;
Figure 2B), in the stratum radiatum (SR, 12.93% at 9 months,
27.71% at 12 months, 14.55% at 18 months; Figure 2C) and in
the stratum lacunosum moleculare (SLM, 93.19% at 9 months,
39.58% at 12 months, 56.08% at 18 months; Figures 1G,H, 2D;
Table 1).
In theDG an increase in CaSR expressionwasmost prominent
in the molecular layer (ML) of 3xTg-AD animals respect to their
controls (15.90% at 9 months, 12.32% at 12 months, 20.98%
at 18 months; Figure 3B) and in the granular cell layer (GCL,
19.33% at 9 months, 10.68% at 12 months, 37.38% at 18 months;
Figures 1I,J, 3C; Table 1). The increase in the molecular layer
was similar in all subdivisions; the inner, middle and outer ML
(data not shown).
Increased level of CaSR labeling in the projections layers
described above doesn’t appear to derive from neuronal somata,
despite its presence in some interneurons cell bodies, but
mainly from the neuropil comprising both dendrites and axons
(Figures 1D,F).
CaSR Increase in Hippocampus Occurs in
the Areas Affected by β-Amyloid
Accumulation
In 3xTg-AD mice intracellular β-amyloid in hippocampal
neurons appears between 4 and 6 months of age and reaches
its maximum at 9 months of age (Figures 4G,H); extracellular
β-amyloid depositions start to mount from 9 to 12 months,
being maximal at 18 months. At 18 months the β-amyloid
plaques are big and expanded through the hippocampus mainly
concentrating in the CA1 subfield (Figures 4E,F,I,J); with later
FIGURE 3 | Modification of CaSR expression in hippocampal DG. Bar
graphs illustrating CaSR-IR IOD within DG subfield between non-Tg controls
and 3xTg-AD mice at 9, 12, and 18 months of age (Ns for non-Tg = 5, 5, 4;
ns for 3xTg-AD = 4, 5, 3, respectively; 3 slices have been analyzed per each
animal). (A) Total DG; (B) Molecular Layer; (C) Granular Cell Layer. Bars
represent means ± SEM (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
appearance in the DG (Noristani et al., 2012; Rodríguez et al.,
2013). In a similar way hyper-phosphorylated Tau protein begins
to be detectable in 3xTg-AD mice at 12 months causing the
formation of tangles by 18 months, and it is also concentrated in
CA1 region affecting all the layers (Figures 4K,L). The increase
of CaSR intensity in the CA1 region follows the same spatio-
temporal pattern as that of β-amyloid deposition (Figures 4A–F),
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FIGURE 4 | CaSR and β-amyloid relationship in hippocampus during AD progression. Confocal micrographs showing the overlapping expression of CaSR
(red) with the accumulation of intraneuronal Aβ (green, anti-Aβ 488) and the formation of plaques in hippocampal pyramidal neurons of 3xTg-AD mice of 12 and 18
months of age respectively. (A,D) CaSR-IR; (B,E) Aβ-IR; (C,F) merge. St Or Stratum Oriens; CA1 PcL CA1 Pyramidal Cell Layer; St Rad Stratum Radiatum. Bar graphs
illustrating the number of Aβ positive cells (G) and the IOD of CaSR (H) within CA1 subfield of hippocampus between non-Tg controls and 3xTg-AD mice at 9 months
of age (***p ≤ 0.001). Brightfield micrographs of CA1 areas of hippocampus of non-Tg and 3xTg-AD mice immunolabeled with anti-Aβ (I,J) and anti-Tau antibody
(K,L) at 12 months of age. St Or, Stratum Oriens; CA1 PcL, CA1 Pyramidal Cell Layer; St Rad, Stratum Radiatum; St Lac Mol, Stratum Lacunosum Moleculare.
while in the DG it appears even before the accumulation of Aβ
becomes evident.
DISCUSSION
In vitro exposure of human cortical astrocytes and neurons to a
truncated form of β-amyloid, the Aβ25–35 peptide, which binds
and activates the CaSR (Dal Prà et al., 2014), stimulated the
intracellular production and secretion of β-amyloid by both cell
types with the subsequent death of a fraction of neurons (Armato
et al., 2013). While neurons were vulnerable to β-amyloid
toxicity, cultured astrocytes survived and they showed a transient
increase of CaSR expression. The cytotoxic effects on neurons
were fully inhibited following addition of CaSR antagonist NPS
2143 to the incubation media. Indeed, the NPS prevented the
death of neurons and it deeply and steadily downregulated the
receptor in the Aβ-treated astrocytes, and completely blocked the
Aβ self-induction mechanism (Armato et al., 2013).
This in vitro study conceptually complements results we
obtained in the 3xTg-AD mice model described in the present
paper; these results further corroborate links existing between
increases in CaSR expression and β-amyloid accumulation. In
the 3xTg-ADmice, intraneuronal β-amyloid starts to accumulate
in the CA1 pyramidal neurons at 4–6 months of age reaching
maximum at 9 months of age, while extracellular β-amyloid
deposits emerge from 12 months of age. Appearance of senile
plaques is associated with specific astrogliosis around the plaques
despite the generalized hippocampal astrocytic atrophy and with
an increase in the density of activated microglia and recruitment
of new ramified microglial cells (Rodríguez et al., 2009, 2010,
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2013; Olabarria et al., 2010). Accumulation of Tau that occurs
later follows similar pattern with maximum presence from 18
months. The 3xTg-AD mouse model not only develops the
typical histopathological hallmarks of Alzheimer’s disease, but
also manifests synaptic dysfunction with impaired long-term-
potentiation (LTP) (Oddo et al., 2003b; Rodríguez et al., 2008).
Analysis of an acute hypoxia/ischemia in rats revealed that
Aβ overproduction due to hypoxic injury is mediated by
CaSR hyperexpression (Bai et al., 2015). Experiments on rat
hippocampal neurons demonstrated that hypoxia induces an
up-regulation of CaSR which in turn promotes the elevation
of cytosolic [Ca2+] thereby producing an increase of BACE1
expression that results in the rise of Aβ40 and Aβ42 generation.
In addition, specific inhibition of CaSR with Calhex 231, an
allosteric antagonist of CaSR, induced a decrease of BACE1 and
Aβ both in vitro and in vivo in hypoxic conditions (Bai et al.,
2015). The prominent effect of the increased expression and
activity of CaSR in hippocampus is confirmed also by analysing
a mouse model of acute ischemic injury where a transient global
cerebral ischemia (TGI) was induced. In this model CaSR was
overexpressed in parallel with GABAB receptor 1 downregulation
and was followed by neuronal death. The administration of the
calcilytic compound NPS89636 through intracerebroventricular
injections after the TGI specifically blocked the activity of
CaSR, restoredGABABR1 expression and protected hippocampal
neurons from cell death. Furthermore, the treatment of TGI
mice with calcilytics significantly improved learning andmemory
(Kim et al., 2014).
Altogether these findings reveal the importance and the
impact which altered expression of CaSR has on maintaining the
normal brain function, supporting the idea that its changes could
contribute to the development and progression of pathologies
such as Alzheimer’s disease and stroke. Our present data in an
AD mouse model show that expression of CaSR is increasing
while neuropathology progresses. Previous works demonstrated
that the administration of Aβ42 oligomers to neuronal and
astrocytic human cell cultures increases the endogenous Aβ42
production and secretion resulting in a progressive death of
neurons. This mechanism of Aβ self-induction, which contribute
to the advance of AD, was demonstrated to be completely
suppressed by adding a specific calcilytic like NPS 2143 to the
cell culture (Armato et al., 2013; Dal Prà et al., 2015; Chiarini
et al., 2016). It needs to be emphasized that the CaSR could
be a promising target of investigation for not only further
understanding AD pathology onset and spread but also for
evaluating new therapeutic solutions.
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